Avid Bioservices Inc (CDMO)

[sulaco]

Mass, appreciate the industry insight

Immuno-onc is not a place for a plodding, slow-grinding mega-BP. The field is moving FAR too quickly.

Case in point. The SOC for melanoma changed so fast this year that PPHM had to axe their melanoma trial with Yervoy because Keytruda beat Yervoy in its head-to-head P3 that came out in 4/2015 at the AACR.

THAT fast. Keytruda (anti-PD1, which also blocks ligands PD-L1 and PD-L2) is now SOC in unresectable melanoma. Yervoy was anti-CTLA-4. So you can see that PPHM couldn't continue with that trial.

A nimble, lean, hungry BP that wants to beat the mega-BPs off the line may very well be completing their DD on PPHM.

Regards,

Joe